A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Stopped The Sponsor decided to terminate the study early due to lack of efficacy. There were no safety concerns related to the study.

Conditions

• Chronic Kidney Disease

Interventions

• DRUG: AZD5718
• DRUG: Dapagliflozin 10 mg
• DRUG: Placebo

Sponsor

AstraZeneca

Collaborators

• [object Object]
• [object Object]